Page URL:

Personal genomics company 23andMe awarded Parkinson's gene patent

6 June 2012
Appeared in BioNews 659

23andMe, a personal genomics company, announced last week that it had been successfully awarded a patent for a genetic variant which appears to protect against a high-risk mutation for Parkinson's disease.

That high-risk mutation is called G2019S and about half of all carriers go on to develop Parkinson's Disease. 23andMe, which compiles genetic data from participants, discovered a large cohort of individuals who carried the G2019S mutation but did not have Parkinson's Disease. In examining this cohort, the company discovered the potentially protective nature of the gene SGK1.

Anne Wojcicki, co-founder of 23andMe, said that identifying healthy individuals with rare genetic variants was 'akin to finding a needle in a haystack and can only be identified with large databases like 23andMe'.

She added: 'These individuals are extremely valuable for us to study as they provide insights into why some people do not develop disease despite having high-risk genetic factors. This could lead to new drug targets or diagnostics'.

But the patenting of a variant in the SGK1 gene is not, as 23andMe acknowledged in an announcement on its blog, without controversy.

Dr Stuart Hogarth, a research fellow at King's College London, has written an open letter to the company where he probes 23andMe's assertion that their patent 'will not prevent individuals from getting access to information or prevent researchers from researching the target'.

The company's announcement on its blog also provoked concern from 23andMe users about how 23andMe would enforce the patent, and why feedback was not sought from customers before the application was made.

One customer wrote: 'I had assumed that 23andMe was against patenting genes and felt in total cahoots all along with you guys. If I'd known you might go that route with my data, I'm not sure I would have answered any surveys'.

In response Anne Wojciki emphasised the core values of 23andMe, its 'mission to improve lives' and the commercial reality of developing new drugs and treatment.

'Patents give organizations researching and developing new drugs confidence that their significant investments will be commercially viable', she said. 'Often the only way a company will even think about pursuing a drug lead is if they have assurance that they can recoup their investment. Having patent protection over the entire line of discovery gives a company confidence to invest in this resource-intensive process'.

23andMe's research was conducted in collaboration with Scripps Medical Institute and funded by the Michael J Fox Foundation for Parkinson's Research.

23andMe Discovers Genetic Variant That May Protect Those at High Risk for Parkinson’s Disease
23andMe Press Release |  28 May 2012
23andMe stakes a claim on Parkinson's gene
Fierce Biotech |  29 May 2012
Announcing 23andMe’s First Patent
The Spitoon |  28 May 2012
Still patently unclear?
Gene Values |  30 May 2012
10 January 2014 - by Dr Kimberley Bryon-Dodd 
Patients in a clinical trial to treat Parkinson's disease with a form of gene therapy have showed signs of significant improvements in their motor-function, according to a report published in the Lancet...
9 December 2013 - by Ruth Saunders 
Genetic testing company 23andMe, which last week suspended the sale of its health-related genetic tests, is now facing a class action lawsuit in California over its marketing claims....
20 August 2012 - by Ruth Saunders 
23andMe, a US-based personal genomics company, has sought regulatory approval from the Food and Drug Administration for seven of its genetic tests....
9 July 2012 - by Dr Megan Allyse 
When US based, direct-to-consumer genetic testing company 23andMe announced last month that it had obtained a patent on a method for determining predisposition to Parkinson's disease, it highlighted, perhaps inadvertently, a growing area of unresolved tension between clinical, commercial and research interests....
9 July 2012 - by Ruth Saunders 
Two novel gene variants linked to breast size may also also influence the risk of breast cancer, according to a study carried out by US genetics company 23andMe....
27 February 2012 - by Luciana Strait 
A new genetic mutation linked to a greater risk of developing breast cancer has been shown to interact with the well-known breast cancer-causing gene BRCA1...
19 December 2011 - by Nishat Hyder 
A patent for a diagnostic test is currently under consideration by the US Supreme Court. The eventual decision may have profound implications for the burgeoning 'personalised medicine' industry which often relies on DNA tests to guide physicians in choosing tailored therapies for patients...
14 November 2011 - by Martin Turner 
In what appears to be the end of a long running legal saga, a ruling by the UK's Supreme Court has found in favour of a patent for a gene and the protein sequence it encodes. Lawyers say that the ruling will make it easier to patent discoveries which do not have a clear demonstrated application, a result that will largely please the private bioscience industry but may alarm many who believe that human genes should not be patentable....
6 June 2011 - by Rosemary Paxman 
Direct-to-consumer (DTC) genetic tests provide an inaccurate prediction of disease risk and offer little benefit to consumers, scientists claim...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.